News & Updates

Show Multimedia Only

Investigational DP2 antagonist strikes out in eosinophilic asthma

13 Mar 2022

The prostaglandin D2 receptor 2 (DP2) antagonist GB001 does not appear to significantly lower the risk of disease worsening in patients with moderate-to-severe eosinophilic asthma, according to data from a phase IIb trial.

Investigational DP2 antagonist strikes out in eosinophilic asthma

13 Mar 2022

PPIs contribute to small increase in pancreatic cancer risk

13 Mar 2022

Individuals exposed to high cumulative doses of proton pump inhibitors (PPIs) have a slightly elevated risk of pancreatic cancer, a study reports.

PPIs contribute to small increase in pancreatic cancer risk

13 Mar 2022

QI initiative reduces time to administer biologics, ER visits in IBD

13 Mar 2022

A quality improvement (QI) intervention is associated with reduced medication administration times for biologic therapy by fast-tracking provider-dependent steps and with fewer emergency room (ER) visits, reveals a recent study.

QI initiative reduces time to administer biologics, ER visits in IBD

13 Mar 2022

KEYNOTE-590 extended follow-up shows pembro + chemo maintains survival in advanced oesophageal cancer

12 Mar 2022 by

First-line treatment with pembrolizumab + chemotherapy maintains overall survival (OS) and progression-free survival (PFS) in patients with advanced or metastatic oesophageal cancer, according to an additional 12-month follow-up of the KEYNOTE-590* study presented at ASCO GI 2022.

KEYNOTE-590 extended follow-up shows pembro + chemo maintains survival in advanced oesophageal cancer

12 Mar 2022

Endovascular therapy has added value in patients with acute large vessel occlusion

11 Mar 2022 by

Endovascular therapy (EVT) in addition to medical therapy appeared to improve outcomes in patients with acute large vessel occlusion (LVO) with large ischaemic core following a stroke, according to results of the RESCUE-Japan LIMIT* trial.

Endovascular therapy has added value in patients with acute large vessel occlusion

11 Mar 2022

Which melphalan formulation works better against engraftment syndrome?

11 Mar 2022

The incidence of engraftment syndrome (ES), a common complication of autologous haematopoietic cell transplantation (HCT), is comparable between melphalan formulations among patients with multiple myeloma and immunoglobulin light chain amyloidosis, reveals a study.

Which melphalan formulation works better against engraftment syndrome?

11 Mar 2022

Obinutuzumab + SoC improves renal responses in LN patients

11 Mar 2022 by

The addition of obinutuzumab, a humanized type II anti-CD20 monoclonal antibody that induces potent B-cell depletion, to a background of standard-of-care (SoC) therapy led to improved renal responses in patients with proliferative lupus nephritis (LN) compared with SoC alone, findings from the phase II NOBILITY trial have shown.

Obinutuzumab + SoC improves renal responses in LN patients

11 Mar 2022

Recent updates on HIV prevention and treatment in Singapore

11 Mar 2022

Human immunodeficiency virus (HIV) infection remains a public health priority in Singapore. The National Centre for Infectious Diseases (NCID) established the National HIV Programme (NHIVP) to coordinate the country-wide HIV response in collaboration with clinicians, healthcare professionals, public health practitioners, and other stakeholders. The NHIVP develops and updates evidence-based guidelines and best practices on HIV prevention, testing, and treatment. This article summarizes the best practices and key updates on prescribing of HIV pre-exposure prophylaxis (PrEP), and use of antiretroviral therapy (ART) in Singapore.

Recent updates on HIV prevention and treatment in Singapore

11 Mar 2022

Shorter antibiotic regimen enough in kids with pneumonia?

10 Mar 2022 by

Children with non-severe community-acquired pneumonia (CAP) may benefit from a 5-day antibiotic regimen compared with the current standard regimen of 10 days, according to results of the US-based SCOUT-CAP trial.

Shorter antibiotic regimen enough in kids with pneumonia?

10 Mar 2022

OS benefit of NIVO + IPI holds out through 5 years over sunitinib in sarcomatoid RCC

10 Mar 2022 by

First-line treatment with a combination of nivolumab plus ipilimumab (NIVO + IPI) continues to show long-term survival benefits over sunitinib out to 5 years in patients with advanced clear-cell renal carcinoma (RCC) with sarcomatoid features, according to the CheckMate 214 study presented at GUCS 2022.

OS benefit of NIVO + IPI holds out through 5 years over sunitinib in sarcomatoid RCC

10 Mar 2022

News & Updates

Filter by Specialty:

Specialty:

Investigational DP2 antagonist strikes out in eosinophilic asthma

Investigational DP2 antagonist strikes out in eosinophilic asthma

PPIs contribute to small increase in pancreatic cancer risk

PPIs contribute to small increase in pancreatic cancer risk

QI initiative reduces time to administer biologics, ER visits in IBD

QI initiative reduces time to administer biologics, ER visits in IBD

KEYNOTE-590 extended follow-up shows pembro + chemo maintains survival in advanced oesophageal cancer

KEYNOTE-590 extended follow-up shows pembro + chemo maintains survival in advanced oesophageal cancer

Endovascular therapy has added value in patients with acute large vessel occlusion

Endovascular therapy has added value in patients with acute large vessel occlusion

Which melphalan formulation works better against engraftment syndrome?

Which melphalan formulation works better against engraftment syndrome?

Obinutuzumab + SoC improves renal responses in LN patients

Obinutuzumab + SoC improves renal responses in LN patients

Recent updates on HIV prevention and treatment in Singapore

Recent updates on HIV prevention and treatment in Singapore

Shorter antibiotic regimen enough in kids with pneumonia?

Shorter antibiotic regimen enough in kids with pneumonia?

OS benefit of NIVO + IPI holds out through 5 years over sunitinib in sarcomatoid RCC

OS benefit of NIVO + IPI holds out through 5 years over sunitinib in sarcomatoid RCC